Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline... see more

Recent & Breaking News (PINL:ZLDPF)

Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022

GlobeNewswire November 3, 2022

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting

GlobeNewswire November 1, 2022

Zealand Pharma major shareholder announcement: Polar Capital

GlobeNewswire October 11, 2022

Zealand Pharma major shareholder announcement: Van Herk Investments

GlobeNewswire October 10, 2022

Zealand Pharma completes registration of capital increase

GlobeNewswire October 7, 2022

Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million

GlobeNewswire October 4, 2022

Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares

GlobeNewswire October 4, 2022

Total number of shares and voting rights in Zealand Pharma at September 30, 2022

GlobeNewswire September 30, 2022

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

GlobeNewswire September 30, 2022

Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)

GlobeNewswire September 21, 2022

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

GlobeNewswire September 19, 2022

Zealand Pharma grants warrants to employees in Denmark

GlobeNewswire September 13, 2022

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

GlobeNewswire September 8, 2022

Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 7, 2022

Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)

GlobeNewswire September 7, 2022

Total number of shares and voting rights in Zealand Pharma at August 31, 2022

GlobeNewswire August 31, 2022

Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

GlobeNewswire August 24, 2022

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

GlobeNewswire August 18, 2022

Zealand Pharma Announces Financial Results for the First Half of 2022

GlobeNewswire August 11, 2022

Updated notice to holders of ADSs regarding termination of Deposit Agreement

GlobeNewswire August 8, 2022